ClinicalTrials.gg
RecruitingNCT06527456INDIGOUpdated Apr 14, 2026

Intervention With General Practitioners to Improve Women's Participation in Cervical Cancer Screening

An interventional study of participation of the general practitioner in Cervical Cancer, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 1 site in France. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Centre Hospitalier Intercommunal Creteil · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
11,200
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 147 studies in Uterine Cervical Neoplasms with a site in France — 31 open to participants now, 46 under way, 5 of them phase 3. Uterine Cervical Neoplasms · France.

Planned enrollment
4th of 117
11,200 · median 210
Started
2026
with 3 others
No phase
45 of 147
9 open now
Primary completion
2027-08
later than 22 of 45 live
Registered
121st of 147
by date

Among the 147 studies in Uterine Cervical Neoplasms with a site in France, this one is the 4th largest by planned enrollment of the 117 interventional ones that give a count, is one of 4 that started in 2026, is one of 45 with no phase, reaches primary completion later than 22 of the 45 other live ones, and was the 121st registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

31 of the 147 studies in Uterine Cervical Neoplasms with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Uterine Cervical Neoplasms with a site in France, or all of them as a file.
02

Study summary

In France, cervical cancer is the 12th most common female cancer with nearly 3,000 new cases per year.

Since 2018, a national Organized Cervical Cancer Screening program (DOCCU) has been set up and concerns all asymptomatic women aged 25 to 65.

This program, managed by the Regional Cancer Screening Coordination Centers (CRCDC), invites women who have not taken a sample within the recommended time frame to consult for screening. However, only 59% of patients participated.

The intervention of the general practitioner, an essential player in prevention, could allow for better awareness.

The objective of the INDIGO study is to evaluate the effectiveness of the intervention of a general practitioner on the participation rate in the DOCCU of patients who are not up to date with their screening.

Read the detailed description

This is a cluster-randomized trial. Randomization will be performed at the GP practice level to limit the potential contamination bias between doctors within the same practice. GP practices will be randomized either to the 'usual practice' arm or the 'intervention' arm."

If they are in the "intervention" group, they or one of the professionals in their team will contact the patient (phone call, SMS, email, etc.), to encourage her to make an appointment to carry out the screening. Contact arrangements are left to the discretion of each general practitioner..

If they are in the "Usual practice" group, they will use their usual practices to encourage screening.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman aged 25 to 65 living in Ile-De-France
  • Eligible for DOCCU (not hysterectomized, not followed for a pre-cancerous or cancerous lesion of the cervix)
  • Having declared the investigating general practitioner as a treating physician (MT) and whose MT practices in the territory of a CPTS in the UPEC area
  • Affiliate to a social security scheme or beneficiary of such a scheme

Exclusion criteria

Exclusion Criteria:

  • Patient already included in a study on DOCCU
  • Patient excluded from organized screening (cervical cancer, hysterectomy).
  • Patient's opposition to participating in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11,200 participants (estimated)

Study arms

  • No intervention
    usual practice

    the doctor will use their usual practices to encourage screening.

  • Experimental
    Intervention

    the general practitioner or one of the professionals on their team will contact the patient (phone call, SMS, email, etc.), to encourage them to make an appointment to carry out the screening

    Other: participation of the general practitioner

Interventions

  • Otherparticipation of the general practitioner

    participation of the general practitioner in encouraging cervical cancer screening

06

What researchers measure

Primary outcomes

  1. screening participation rate

    percentage of patients who had a screening Cervical Sample (cytology or HPV test within a timeframe satisfying the HAS recommendations according to age) among patients eligible for screening aged 25 to 65 years

    Time frame: 12 month

07

Study locations

1 of 1 sites recruiting
  • Médecins généralistes dans le bassin de l'UPEC
    Créteil, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 19 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Jul 30, 2024
StartActual
Jan 21, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06527456
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jan 21, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Emilie FERRAT
Contact
emilie.ferrat@u-pec.fr
0633085225
Camille JUNG
Contact
camille.jung@chicreteil.fr
01.57.02.22.68

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion